Details

Autor(en) / Beteiligte

• Venugopal, Nayana
• Acharya, Pooja
• Zarei, Mehrdad
• Talahalli, Ramaprasad Ravichandra

Titel

Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis

Ist Teil von

• Inflammopharmacology, 2019-10, Vol.27 (5), p.923-931

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• Background and aims Though cyclooxygenase inhibitors are employed in rheumatoid arthritis treatment, modulators of leukotrienes are underexplored. We investigated the therapeutic potential of montelukast, a known cysteinyl leukotriene receptor-1 (CysLT1) inhibitor in an experimental rat model of arthritis. Methods Arthritis was induced in rats, and montelukast (5 mg/kg body wt.) was administered prophylactically (PAM) and therapeutically (TAM) through oral route. Results and discussion Blood and joint tissue markers of oxidative stress (lipid peroxidation, protein carbonyls, and nitric oxides) were significantly ( p  < 0.05) reduced in montelukast administered rats. Paw inflammation, RA markers (RF and CRP), eicosanoids (PGE 2 , LTB 4 , and LTC 4 ), cytokines (IL-1β and MCP-1), activity of hydrolytic enzymes (collagenase, elastase, and hyaluronidase), expression of matrix metalloproteinases (MMP), and EP-4 receptor were significantly ( p  < 0.05) reduced in montelukast administered rats. This study established that leukotriene inhibition through montelukast lowered the severity of arthritis and thus a potential strategy for reducing the severity of arthritis. Graphic abstract